At MDUFA VI meeting, FDA revealed fee updates, program changes and next steps

By Laura DiAngelo, MPH

FDA and industry leaders have provided new details on the proposed MDUFA VI agreement, offering a clearer view of how the next medical device user fee program could take shape. Rather than introducing major new initiatives, the proposal emphasizes core review processes alongside targeted changes to fees, pre-submissions and existing programs. As the agreement moves toward Congress, those details offer important signals about the priorities that could shape the next five-year user fee cycle.

This AgencyIQ analysis examines the latest MDUFA VI developments, what they could mean for device companies and the next steps to watch in the reauthorization process.

Fill out the form to read the full analysis.